Abstracts tagged "COVID-19"

Abstract Number: 0039 • ACR Convergence 2025
Hemophagocytic Lymphohistiocytosis Gene Variants in Severe COVID-19 Cytokine Storm Syndrome
randy Cron¹, Abhishek Kamath¹, Mingce Zhang¹, Devin Abhser², Lesley Jackson¹ and Walter Winn Chatham³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Kaiser Permanente Research Bank, Oakland, CA, ³University of Nevada, Las Vegas, Las Vegas, NV
Background/Purpose: Severe COVID-19 infection resulting in hospitalization shares features with frequently fatal cytokine storm syndromes (CSS), such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome…
Abstract Number: 1897 • ACR Convergence 2025
Changes in SLE Mortality During and After the COVID-19 Pandemic
Laura Hernandez¹ and Ram Singh², ¹University of California, Los Angeles, Murrieta, CA, ²UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are vulnerable to infections due to both underlying immune dysfunction and the use of immunosuppressive therapies. Hence, it…
Abstract Number: 1636 • ACR Convergence 2025
The Impact of Arthritis on Self-Management Activities of West Virginia Adults with Type 2 Diabetes During the COVID-19 Pandemic
Dina Maruca¹, Teresa Brady², Gerald Hobbs, Jr.¹ and Ranjita Misra¹, ¹West Virginia University, Morgantown, WV, ²Clarity Consulting and Communications, Atlanta, GA
Background/Purpose: One-third of adults with Type 2 diabetes (T2D) also have arthritis. West Virginia (WV), the 3rd most rural US state, has the highest prevalence…
Abstract Number: 1576 • ACR Convergence 2025
Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study
kyung-Ann Lee¹, Hyun-Sook Kim² and Boda Nam³, ¹Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, ²Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, ³Chung-Ang University Hospital, Seoul, Republic of Korea
Background/Purpose: Pulmonary fibrosis is a recognized sequela of severe COVID-19 pneumonia, but its additive impact on pre-existing interstitial lung disease (ILD)—particularly in patients with connective…
Abstract Number: 1493 • ACR Convergence 2025
Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods
Lilliana Serrano-Arroyo, César Rosado-Bloise and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: The post-acute sequelae of SARS-CoV-2 infection may involve low-grade inflammation, immune dysregulation, and endothelial dysfunction. Therefore, it would not be surprising if SARS-CoV-2 negatively…
Abstract Number: 1305 • ACR Convergence 2025
Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) – a multicenter study
Nina Shirman¹, Liora Harel², Gil Amarilyo³, Kfir Kaidar⁴, Yonatan Butbul Aviel⁵, Merav Heshin Bekenstein⁶, Mohamad Hamad Saied⁷, Ofra Goldzweig⁸, Adi Miler⁹ and Yoel Levinsky¹⁰, ¹Schneider children's medical center of Israe, Tel Aviv, Israel, ²Schneider Children's Medical center, Nettnja, Israel, ³Schneider Children's Medical Center of Israel, Kibbutz Maggal, Israel, ⁴Pediatric rheumatology, Schneider children's medical center of Israel, Petah Tikva, Israel, ⁵Pediatric rheumatology, Technion Faculty of Medicine, Haifa, Israel, ⁶Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ⁷Carmel Medical Centre, Technion Faculty of Medicine, Haifa, Israel, ⁸Pediatric rheumatology unit, Kaplan medical canter, Rehovot, Israel, ⁹Pediatric rheumatology unit, Technion Faculty of Medicine, Haifa, Israel, ¹⁰Schneider Children's Medical Cenetr of Israel, Tel Aviv University, JERUSALEM, Israel
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is an autoinflammatory disease following SARS-CoV-2 exposure. The optimal treatment strategy remains under investigation, though intravenous immunoglobulin (IVIG)…
Abstract Number: 1280 • ACR Convergence 2025
Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
Yonatan Butbul Aviel¹, Arad Dotan², Dana Arnheim² and Cynthia Freiberg³, ¹Rambam Health Care Campus, Haifa, Israel, ²Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel, Tel Aviv, Israel, ³Maccabi Healthcare Services, Tel Aviv, Israel, Tel Aviv
Background/Purpose: During the COVID-19 pandemic there were reports of an increased association between COVID 19 and various autoimmune diseases (AID) in adults. This study aims…
Abstract Number: 1189 • ACR Convergence 2025
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
Valerie Devauchelle¹, Swati Ghanshani², CAROLE SIPS³, Rainer Hillenbrand³, Carol Lau⁴, Wolfgang Hueber⁵, Claire Bonal³ and Stephen Oliver⁶, ¹UBO, Brest, France, ²Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ³Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via dual mechanism: depletion of B…
Abstract Number: 0131 • ACR Convergence 2024
Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study
Carol Hitchon¹, Dawn Bowdish², Gilles Boire³, Paul Fortin⁴, Louis Flamand⁵, Vinod Chandran⁶, Roya M Dayam⁷, Anne-Claude Gingras⁸, Catherine Card⁹, Ines Colmegna¹⁰, Maggie Larche², Gil Kaplan¹¹, Luck Lukusa¹², Jennifer Lee¹² and Sasha Bernatsky¹³, and SUCCEED investigative team, ¹University of Manitoba, Winnipeg, MB, Canada, ²McMaster University, Hamilton, ON, Canada, ³Retired, Sherbrooke, QC, Canada, ⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁵Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, ⁶University of Toronto, Toronto, ON, Canada, ⁷Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada, ⁸Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, ⁹National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada, ¹⁰The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹University of Calgary, Calgary, AB, Canada, ¹²The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Given ongoing SARS-CoV-2 circulation, COVID-19 vaccination response in immune-mediated inflammatory disease (IMID) remains a key issue, particularly regarding effects of common immunosuppressives like methotrexate…
Abstract Number: 0246 • ACR Convergence 2024
Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies
Elana Shaw, Stephanie Glavaris, Brian Mog, Alexander Pearlman, Sarah DiNapoli, Jin Liu, Kyle J. Kaeo, Kenneth W. Kinzler, Chetan Bettegowda, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially deadly immune complication after infection with SARS-CoV-2. In patients with MIS-C, a striking…
Abstract Number: 1880 • ACR Convergence 2024
Statewide Burden of Osteoarthritis in India and Its Trend from 1990-2021: A Benchmarking Analysis
Rafael Sanchez-Dopazo,¹, malay rathod², Ashwinikumar Shandilya³, Janmay Vala⁴, Eva Kalra⁵, Tapan Giri⁶, Saif Syed⁷, Mohit Lakkimsetti⁸, Juhi Patel⁹, VISHRANT AMIN¹⁰ and Hardik Desai¹¹, ¹Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ²Monmouth Medical Center, Rutgers University, Ewing, NJ, ³Rural Medical college. Pravara institute of medical sciences., Ahmednagar, India, ⁴Terna Medical College, Navi Mumbai, Maharashtra, India, ⁵Trident Medical Cente, Charleston, SC, ⁶BJ Medical College, Pune, Pune, Maharashtra, India, ⁷Royal college of Surgeons,Dublin,Ireland, Dublin, Dublin, Ireland, ⁸Mamata Medical College,Khammam, Khammam, Telangana, India, ⁹GMERS MEDICAL COLLEGE VALSAD, 382330, Gujarat, India, ¹⁰GMERS MEDICAL COLLEGE VALSAD, Ahmedabad, India, ¹¹Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: Osteoarthritis (OA) imposes a significant health burden globally, with India experiencing substantial demographic and epidemiological changes over the past three decades. This study addresses…
Abstract Number: 2616 • ACR Convergence 2024
Associations of Circulating Inflammatory Cytokines with Long COVID Among Patients with Systemic Autoimmune Rheumatic Diseases
Jeffrey Sparks¹, Xiaosong Wang², Pui Lee³, Kailey Brodeur⁴, Miao Lin⁵, Naomi Patel⁵, Yumeko Kawano⁶, Abigail Schiff⁷, Andrew King⁵, Jennifer Hanberg⁶, Shruthi Srivatsan⁵, Emily Kowalski⁶, Colebrook Johnson⁵, Kathleen Vanni⁶, Zachary Williams⁵, Grace Qian², Caleb Bolden⁵, Kevin Mueller⁶, Katarina Bade⁶, Alene Saavedra⁶, Rathnam Venkat⁸ and Zachary Wallace⁹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Boston Children's Hospital, Newton, MA, ⁴Boston Children's Hospital, Cumberland, RI, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Cambridge, MA, ⁸Tufts University School of Medicine, Boston, MA, ⁹Massachusetts General Hospital, Newton, MA
Background/Purpose: While the incidence of severe acute COVID-19 has decreased, post-acute sequelae of COVID-19 characterized by prolonged symptoms, or ‘long COVID,’ is common and associated…
Abstract Number: 0132 • ACR Convergence 2024
Patients with Systemic Autoimmune Rheumatic Diseases Remain at Risk for Hospitalization for COVID-19 Infection in the Omicron Era (2022-2024): A Retrospective Cohort Study
Naomi Patel¹, Andrew King¹, Shruthi Srivatsan¹, Xiaosong Wang², Emily Kowalski³, Kathleen Vanni³, Grace Qian², Jennifer Hanberg³, Katarina Bade³, Alene Saavedra³, Kevin Mueller³, Zachary Williams¹, Colebrook Johnson¹, Madison Negron¹, Jeffrey Sparks⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: The risk of severe acute COVID-19 infection has substantially decreased since the start of the pandemic. However, the risk of severe acute COVID-19 outcomes…
Abstract Number: 0366 • ACR Convergence 2024
Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study
Koushan Kouranloo¹ and Chris Wincup², ¹Internal Medicine Resident., London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Clinicians are encouraged to consider patient preferences for offering face-to-face vs virtual consultations. This adaptability is particularly important to rheumatologists caring for patients with…
Abstract Number: 1888 • ACR Convergence 2024
Anti-Spike Antibodies Protect Against COVID-19 Infection in Immune-Mediated Inflammatory Diseases: Findings from the SUCCEED Study
Jeremiah Tan¹, J. Antonio Avina-Zubieta², Paul Fortin³, Anne-Claude Gingras⁴, Maggie Larche⁵, Dawn Bowdish⁵, Claudie Berger⁶, Ines Colmegna⁷, Carol Hitchon⁸, Diane Lacaille², Dawn Richards⁹, Nadine Lalonde¹⁰, Ayesha Kirmani¹, Jennifer Lee¹¹ and Sasha Bernatsky⁶, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁴Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Canadian Arthritis Patients Alliance, Toronto, ON, Canada, ¹⁰COVID-19 Global Rheumatology Alliance, London, ON, Canada, ¹¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: People with immune-mediated inflammatory diseases (IMIDs) may be more vulnerable to severe COVID-19 outcomes. COVID-19 vaccination is a key element in mitigating this risk.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].